Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00514-5
Affiliations:
5
Authors:
11
Go to article
Institutions Authors Share
Netherlands Cancer Institute (NKI), Netherlands
11.000000
11.000000
 1.00
Interested in Oncology and Carcinogenesis?